A simple and highly sensitive fluorimetric high-performance liquid chromatographic (HPLC) method was developed for the determination of amantadine in plasma. After a single-step extraction from plasma (50 µl) with toluene, the drug and 1-(1-adamantyl)ethylamine (internal standard) were converted into the corresponding fluorescent derivatives by reaction with 3,4-dihydro-6,7-dimethoxy-4-methyl-3-oxo-quinoxaline-2-carbonyl chloride, a fluorescence derivatization reagent for amines, in the presence of triethylamine. The derivatives were separated within 20 min on a reversed-phase column (YMCPack C8) using isocratic elution with methanol-acetonitrile-water (35:35:30, v/v) and detected spectrofluorimetrically at 500 nm with excitation at 400 nm. The detection limit for amantadine added to plasma was 360 fmol (54 pg) ml-1 plasma (18 fmol on column) at a signal-to-noise ratio of three.
Amantadine hydrochloride, 1-tricyclo[3.3.1.13'~]-decylamine monohydrochloride, has been widely used as the first choice drug for Parkinson's disease. For the safety and effective administration of the drug to the patients, the informations concerning the pharmacokinetic analysis from patients having various types of clinical backgrounds are helpful. For this purpose, several methods based on gaschromatography1'2 and high-performance liquid chromatography (HPLC) with UV detection3 have been developed for the determination of amantadine in human plasma. We also have reported an HPLC method with fluorescence detection.4s However, these methods are not simple and need a tedious clean-up procedure such as several steps of purification by liquid-liquid extraction. Recently, a fluorimetric HPLC method based on solid-phase derivatization of the drug with 9-fluoreneacetic acid has been developed to overcome this problem.6 Although this method is fairly simple, it requires expensive apparatus. Furthermore, all the methods reported have limited sensitivity and thus require a large amount of plasma (ca. 1 ml). Hence, a simple, reproducible and sensitive assay for plasma amantadine is needed.
We have previously developed a highly sensitive fluorimetric HPLC method for the determination of primary and secondary amines.' The method is based on the derivatization reaction of the amines with 6,7-dimethoxy-4-methyl-3-oxo-quinoxaline-2-carbonyl chloride (DMEQ-COC1), a sensitive and selective fluorescence derivatization reagent for amines. The HPLC method with DMEQ-COCI has been successfully applied to the determination of biologically important amines, R-phenethylamine8 and 1,2,3,4-tetrahydroisoquinoline.9 Recently, we found that DMEQ-0001 also reacts with amantadine under almost the same derivatization conditions to give a highly fluorescent derivative (Fig. 1 ). This study was aimed at establishing a simple and highly sensitive fluorimetric HPLC method utilizing DMEQ-COCI for the determination of amantadine in human plasma. 1-(1-Adamantyl)ethylamine (AEA), which does not occur in biological fluids, was used as an internal standard (IS) for the precise determination. Amantadine concentrations in plasma from four healthy male volunteers, after oral administration of the drug, were measured by the established method. A Hitachi (Tokyo, Japan) L-7100 highperformance liquid chromatograph equipped with a high-pressure sample injector (20-µ1 loop) and a Hitachi L-7480 spectrofluorometer fitted with a 15-µl flow-cell were used. It was operated at an excitation wavelength of 400 nm and an emission wavelength of 500 nm. The DMEQ derivatives of amantadane and AEA (IS) were separated on a YMC Pack Cs (250 x 4.6 mm i.d.; particle size, 5 µm) (Yamamura Chemical Labs., Kyoto, Japan) by isocratic elution with a mixture of methanol, acetonitrile and water (35: 35: 30, v/v) as eluent. The flow rate of the mobile phase was 1.0 ml min-'. The column temperature was ambient (15-25° C). Uncorrected fluorescence excitation and emission spectra of the eluate were measured with a Hitachi 650-60 fluorescence spectrophotometer fitted with a 20-µ1 flow-cell; the spectral bandwidths were 5 nm in both the excitation and emission monochromators.
Chemicals and materials
All chemicals were of analytical-reagent grade, unless noted otherwise. Amantadine and 1-(1-adamantyl)ethylamine were obtained from Sigma (St. Louis, MO, USA). De-ionized and distilled water, purified with a Milli-Q II (Millipore, Milford, MA, USA) system, was used for all aqueous solutions. DMEQ-COCI was prepared as described previously' ; it is now commercially available from Dojindo Labs. (Kumamoto, Japan). DMEQ-0001 solution (1.0 mM) was prepared in acetonitrile and could be used within a day. Triethylamine solution (5.0 mM) was prepared in acetonitrile. Amantadine stock solution (1.0 x 10-4 M) was prepared in ethanol and stored at -20° C until use. The solution was diluted further with water to the desired concentrations before use.
Plasma samples
Healthy male volunteers were given a 50 mg single oral dose of amantadine.
After administration of the drug, blood samples were withdrawn at 1, 2, 3, 6 and 10 h and the heparinized plasma were used as the samples. The drug-free plasma samples were obtained from healthy volunteers.
The plasma samples were frozen on dry-ice immediately after collection and stored at -20° C before use.
Extraction and derivatization procedure A 50-µ1 aliquot of plasma was pipetted into a 10-ml screw-capped test tube together with 10 µl of the IS (1.0 µg ml-1) solution, 50 µl of 1 M NaOH and 2 ml of toluene. After vortex-mixing for ca. 2 min, the mixture was centrifuged at 1000 g for 10 min. The supernatant (1.5 ml) was transferred to another tube and was evaporated to dryness under a nitrogen stream. To the residue were added 1.0 mM DMEQ-COCI solution (100 µl) and 5.0 mM triethylamine solution (50 µl). The resulting mixture was allowed to stand at room temperature (15-40° C) for 5 min. A 20-µ1 portion of the final reaction mixture was injected into the chromatograph.
The calibration graph was prepared as in the above procedure, except that 10 µl of the AEA (IS) solution was replaced with AEA solutions each containing 0.1 -50 ng of amantadine. The net peak height ratios of the drugs and AEA were plotted against the concentrations of the spiked drug.
Results and Discussion

HPLC and derivatization conditions
The best separation of the DMEQ derivatives of amantadine, ABA (IS) and reagent blank components was achieved on a YMC-Pack C8 reversed-phase column with methanol-acetonitrile-water (35:35:30, v/v) as a mobile phase. Fig. 2 shows a typical chromatogram obtained with a mixture of amantadine and AEA. Amantadine and AEA gave single peaks and had retention times of 10.5 and 15.7 min, respectively. All the peaks were completely separated and eluted within 20 min. The fluorescence excitation (maximum, 400 nm) and emission (maximum, 500 nm) spectra of the DMEQ derivatives of amantadine and AEA in the eluates from the column were virtually identical with those of DMEQ-COC1 in the mobile phase. The derivatization reaction of amantadine and AEA with DMEQ-0001 apparently occurred even at 0°C; higher temperature allowed the fluorescence to develop more rapidly (Fig. 3) . At 15 -40°C, the peak heights for the drug and AEA were almost maximal after heating for 1 min. Thus, heating for 5 min at room temperature was employed in the procedure. The DMEQ derivatives in the final mixture were stable and gave constant peak heights for at least 48 h in daylight at room temperature.
Triethylamine was used to facilitate the derivatization of amantadine and AEA with DMEQ-000I. Maximum and constant peak heights could be attained at triethylamine concentrations in the solution in the range of 1-15 mM; 5.0 mM was selected as optimum. The most intense peaks were obtained at concentrations greater than 0.5 mM of DMEQ-0001 solution for amantadine and AEA; 1.0 mM was used in the procedure. Among the solvents examined for the derivatization reaction (benzene, toluene, acetone, chloroform, diethyl ether, methanol, ethanol, acetonitrile, N,N-dimethylformamide and dimethylsulphoxide), the use of acetonitrile resulted in the most intense peaks in the chromatogram. Therefore, triethylamine and DMEQ-0001 solutions were prepared in acetonitrile.
DMEQ-COCI reacted with various biogenic amines, 3-phenethylamine, ceramide (N-stearoylsphingosine and N-palmytoyl-sphingosine), sphingosine, N, N-dimethylsphingosine, under the recommended derivatization conditions to give the corresponding fluorescent derivatives. However, they had the retention times different from those of amantadine and AEA, and did not interfer with the determination of amantadine. Other substances such as alchohols , 17 different u-amino acids, sugars, ketones, phenols and sulfhydryl compounds gave no fluorescent derivatives under these derivatization conditions.
Determination of amantadine in human plasma
Amantadine and AEA (IS) were extracted effectivelly under alkaline conditions with 2 ml of toluene from plasma as described in Experimental. Fig. 4 shows chromatograms obtained with drugfree plasma (A) and with the same plasma (B) spiked with amantadine and AEA (IS). No interfering peaks arose in drug-free plasma around the retention times of these compounds with only one-step extraction. Peaks 1 and 2 in Fig. 3 were identified as the DMEQ derivatives of amantadine and AEA, respectively, on the basis of their retention times and the fluorescence excitation and emission spectra of the eluates in comparison with the standard compounds, and also by co-chromatography of the standards and the plasma sample with aqueous 40-100 % acetonitrile or aqueous 50-100 % methanol as mobile phase.
A linear relationship was observed between the ratios of the peak heights of amantadine to that of AEA and the amounts of amantadine added to plasma up to at least 1.5 .tg (0.8 tmol) ml-' plasma. The slope of the graph did not change with the plasma used. The linear regression equation [with linear correlation coefficients (n=6)] of the graph for amantadine was y=0.0104x -0.0962 (r=0.9992), where y and x are peak-height ratio and the concentration (ng ml"1 in plasma) of the drug, respectively. This result shows that the present internal standard method permits the determination of amantadine in plasma over a wide range of concentrations. The recovery of amantadine added to pooled normal human plasma (100 ng ml-') was 98.6 f 2.5 % (mean ± standard deviation; n=8). The within-day precision was established by repeated determination (n=1O) of amantadine concentrations in plasma spiked with amantadine (100 ng ml-'); the relative standard deviation was 2.7 %.
The detection limit (signal-to-noise ratio=3) for amantadine was 360 fmol (54 pg) ml (18 fmol on column). This sensitivity is much higher than those of the previous methods.' -6 In order to evaluate the proposed method for clinical use, it was applied to monitoring the drug concentrations in plasma samples obtained after a single oral dose of amantadine (50 mg). Fig. 5 shows the time-concentration curves obtained by the plasma samples. The concentrations of amantadine reached a maximum at 2-3 h after oral administration and then decreased gradually in all volunteers. The pattern of the curves was almost identical to those obtained by the other workers.'' Z The present fluorimetric HPLC method using DMEQ-COCI only needs one-step extraction for the pretreatment of the plasma sample. Moreover, it offers higher sensitivity to permit the quantification of amantadine in 50 p1 of human plasma after oral administration of the drug. The method can thus be useful in therapeutic and pharmaceutical investigations of amantadine.
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